ISO 13485 Certification Sedia Biosciences recently obtained ISO 13485 Certification for the production of HIV in vitro diagnostics tests, showcasing their commitment to quality standards. This achievement opens up sales opportunities for partnerships with healthcare facilities seeking reliable diagnostic solutions.

COVID-19 WGS Service The launch of the 'Sedia COVID-19 WGS' whole genome sequencing service positions Sedia Biosciences as a key player in providing cutting-edge tools for novel variant detection and surveillance. This innovative service presents sales opportunities in the realm of pandemic monitoring and research collaborations.

Acquisition of Floragenex Sedia Biosciences' acquisition of Floragenex in 2016 has strengthened their portfolio in the field of HIV treatments and testing. Leveraging the expertise gained from Floragenex, Sedia Biosciences can approach pharmaceutical companies and research institutions for collaborative projects and product integration opportunities.

Merge with Floragenex The merger between Floragenex and Sedia Biosciences has expanded their reach in offering genomics services globally. This strategic collaboration opens doors for sales growth by tapping into Floragenex's existing customer base and exploring synergistic sales strategies.

Market Positioning and Competitors With a revenue range of $0 - 10M and funding of $1.8M, Sedia Biosciences competes in the biotechnology research industry against companies like IMMUNOSTEP and Hytest. Sales professionals can capitalize on Sedia's technology stack, recent expansions, and financial health to differentiate and position the company effectively in the competitive landscape.